| | | December 31, | | ||||
| | | 2016 | | 2015 | | ||
| | | (in thousands) | | ||||
| Deferred tax assets: | | | | | | | |
| Net operating loss carryforward | | $ | 13,815 | | $ | 10,816 | |
| Capitalized research and development expenses | | | 4,666 | | | 3,969 | |
| Research and other credits | | | 1,275 | | | 1,021 | |
| Other | | | 572 | | | 284 | |
| | | | 20,328 | | | 16,090 | |
| Less: Valuation allowance | | | (20,328) | | | (16,090) | |
| Total deferred tax assets | | $ | | | $ | | |
| | | Year Ended December 31, | | ||||
| | | 2016 | | 2015 | | ||
| | | (in thousands) | | ||||
| U.S. Federal provision (benefit) | | | | | | | |
| Loss before provision for income taxes | | $ | (20,137) | | $ | (7,377) | |
| At statutory rate of 35% | | $ | (7,047) | | $ | (2,582) | |
| Change in valuation allowance | | | 4,238 | | | 2,222 | |
| IPO costs | | | 2,434 | | | - | |
| Tax credits | | | (254) | | | (188) | |
| Stock based compensation | | | 178 | | | 7 | |
| Nondeductible expenses | | | 451 | | | 541 | |
| Total | | $ | | | $ | | |